European Medicines Agency says risks of potentially fatal side effects from donanemab outweigh benefits
About us, Contact us, Contribute, Privacy Policy, Review Guidelines, Legal Notice, 2023 MACH MEDIA
Home » EU regulator declines approval for Eli Lillys new Alzheimers drug
European Medicines Agency says risks of potentially fatal side effects from donanemab outweigh benefits